Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Editor's note channel feed
#JPM24 reflections: No politics, no Miami and where the money is in biotech right now
Last year
What we’re doing differently at JP Morgan this year
Last year
Did I ever tell you the one about the drunken biotech awards program I hosted at a Chicago bar?
Last year
Bioregnum
Why Endpoints is bringing a new focus to our manufacturing coverage
Last year
Manufacturing
Expanding the Endpoints newsroom overseas, a special projects hire and our new lead for events
Last year
How you access Endpoints News is changing
3 years ago
I'm hosting some (live!) panels and firesides for our upcoming Boston biotech summit. Please join me there
3 years ago
Announcing three exciting journalists who are joining the Endpoints newsroom
3 years ago
Who are the young biopharma leaders making their mark in the industry? Nominate them for Endpoints' special report
3 years ago
A small change in your inbox each morning
3 years ago
What's next at Endpoints: a bigger, more ambitious newsroom
3 years ago
I’m headed to London soon for #EUBIO22. Care to join me?
3 years ago
Who are the women blazing trails in biopharma R&D? Nominate them for Endpoints' 2022 special report
3 years ago
Endpoints editors select the top trends of 2022: M&A looks hot as IPOs wane, it's time to see some hard data on AI and can accelerated approval remain intact?
4 years ago
Special
Who are the women supercharging biopharma R&D? Nominate them for this year's special report
4 years ago
Endpoints News wants to know: Is your company mandating Covid-19 vaccines?
4 years ago
Pharma
Follow biotechs going public with the Endpoints News IPO Tracker
5 years ago
Who are the young biopharma leaders shaping the industry? Nominate them for Endpoints' special report
5 years ago
What did Endpoints News readers find as the most compelling features of a momentous 2020? Here are the top 10
5 years ago
Our 3rd annual UK biopharma event tops this week — on Zoom — with José Baselga, top biotech CEOs and a look at the global financial scene
5 years ago
Who are the women blazing trails in biopharma R&D and leading the fight against Covid-19? Nominate them for Endpoints' special report
5 years ago
People
Who are the young biopharma leaders shaping the industry? Nominate them for Endpoints' special report
6 years ago
The Endpoints 100: Novartis gets 'poor' grade on data scandal, Ned Sharpless isn't a 'wow' and that Canada drug importation plan is a nonstarter
6 years ago
That feeling you get when you hit the finish line, and then set new goals
7 years ago
Bioregnum
Opinion
First page
Previous page
1
2
3
Next page
Last page